

# Adam T Hill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3252467/publications.pdf>

Version: 2024-02-01

52  
papers

2,972  
citations

257450

24  
h-index

206112

48  
g-index

90  
all docs

90  
docs citations

90  
times ranked

3164  
citing authors

#	ARTICLE	IF	CITATIONS
1	European Respiratory Society guidelines for the management of adult bronchiectasis. <i>European Respiratory Journal</i> , 2017, 50, 1700629.	6.7	788
2	Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2016, 62, 817-823.	5.8	322
3	British Thoracic Society Guideline for bronchiectasis in adults. <i>Thorax</i> , 2019, 74, 1-69.	5.6	291
4	Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1559-1569.	5.6	206
5	Updated BTS Adult Bronchiectasis Guideline 2018: a multidisciplinary approach to comprehensive care. <i>Thorax</i> , 2019, 74, 1-3.	5.6	110
6	European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. <i>European Respiratory Journal</i> , 2021, 58, 2002990.	6.7	95
7	Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1282-1293.	5.6	82
8	Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis. <i>Chest</i> , 2017, 151, 1247-1254.	0.8	81
9	Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. <i>Lancet Respiratory Medicine</i> , 2013, 1, 224-232.	10.7	75
10	Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2014, 2, 455-463.	10.7	74
11	Risk factors for <i>Clostridium difficile</i> infection in hospitalized patients with community-acquired pneumonia. <i>Journal of Infection</i> , 2016, 73, 45-53.	3.3	60
12	In situ identification of Gram-negative bacteria in human lungs using a topical fluorescent peptide targeting lipid A. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	59
13	Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011, 20, 135-140.	2.3	52
14	Blood Neutrophils Are Reprogrammed in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 880-890.	5.6	52
15	National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care?. <i>Thorax</i> , 2014, 69, 292-294.	5.6	48
16	The BRICS (Bronchiectasis Radiologically Indexed CT Score). <i>Chest</i> , 2018, 153, 1177-1186.	0.8	44
17	The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis. <i>European Respiratory Journal</i> , 2018, 52, 1702557.	6.7	42
18	British Thoracic Society national bronchiectasis audit 2010 and 2011: Figure 1. <i>Thorax</i> , 2012, 67, 928-930.	5.6	39

#	ARTICLE	IF	CITATIONS
19	British Thoracic Society guideline for bronchiectasis in adults. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000348.	3.0	37
20	Quality standards for the management of bronchiectasis in Italy: a national audit. <i>European Respiratory Journal</i> , 2016, 48, 244-248.	6.7	33
21	Clinical outcomes and macrolide resistance in <i>Mycoplasma pneumoniae</i> infection in Scotland, UK. <i>Journal of Medical Microbiology</i> , 2013, 62, 1876-1882.	1.8	32
22	A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With <i>Pseudomonas Aeruginosa</i> . <i>Chest</i> , 2017, 152, 368-378.	0.8	31
23	Efficacy and safety of TOBI Podhaler in <i>Pseudomonas aeruginosa</i> -infected bronchiectasis patients: iBEST study. <i>European Respiratory Journal</i> , 2021, 57, 2001451.	6.7	30
24	Clinical and research priorities for children and young people with bronchiectasis: an international roadmap. <i>ERJ Open Research</i> , 2021, 7, 00122-2021.	2.6	28
25	The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. <i>Respiratory Medicine</i> , 2016, 112, 51-58.	2.9	27
26	Macrolides for Clinically Significant Bronchiectasis in Adults. <i>Chest</i> , 2016, 150, 1187-1193.	0.8	25
27	Bronchiectasis Severity Is an Independent Risk Factor for Vascular Disease in a Bronchiectasis Cohort. <i>Chest</i> , 2017, 151, 383-388.	0.8	24
28	Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza. <i>Chest</i> , 2019, 155, 155-167.	0.8	23
29	A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14090.	2.6	21
30	Activated neutrophil fluorescent imaging technique for human lungs. <i>Scientific Reports</i> , 2021, 11, 976.	3.3	18
31	Acute Cough Due to Acute Bronchitis in Immunocompetent Adult Outpatients. <i>Chest</i> , 2020, 157, 1256-1265.	0.8	17
32	MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3206-3217.	2.4	14
33	Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 96-103.	3.5	10
34	Emerging therapies in adult and paediatric bronchiectasis. <i>Respirology</i> , 2018, 23, 1127-1137.	2.3	9
35	Children's Bronchiectasis Education Advocacy and Research Network (Child-BEAR-Net): an ERS Clinical Research Collaboration on improving outcomes of children and adolescents with bronchiectasis. <i>European Respiratory Journal</i> , 2021, 58, 2101657.	6.7	9
36	Validation of the Incremental Shuttle Walk Test as a Clinical End Point in Bronchiectasis. <i>Chest</i> , 2018, 154, 1321-1329.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with <i>P. aeruginosa</i> infection: Design of a dose-finding study (iBEST-1). <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101834.	2.6	8
38	Do processing time and storage of sputum influence quantitative bacteriology in bronchiectasis?. <i>Journal of Medical Microbiology</i> , 2010, 59, 829-833.	1.8	8
39	Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1091-1097.	4.1	6
40	Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics. <i>Current Pulmonology Reports</i> , 2018, 7, 63-71.	1.3	6
41	Management of Community-Acquired Pneumonia in Immunocompromised Adults. <i>Chest</i> , 2020, 158, 1802-1803.	0.8	6
42	“You have to change your whole life”: A qualitative study of the dynamics of treatment adherence among adults with tuberculosis in the United Kingdom. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2021, 23, 100233.	1.3	5
43	Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 737-744.	2.5	4
44	Moving forward: Bronchiectasis and chronic suppurative lung disease in children and adults in the 21st century. <i>Respirology</i> , 2018, 23, 1004-1005.	2.3	3
45	Primary care implications of the British Thoracic Society Guidelines for bronchiectasis in adults 2019. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 24.	2.6	3
46	What’s new in the management of adult bronchiectasis?. <i>F1000Research</i> , 2017, 6, 527.	1.6	3
47	Dysregulation of prostaglandins, leukotrienes and lipoxin A <sub>4</sub> in bronchiectasis. <i>Thorax</i> , 2022, 77, 960-967.	5.6	2
48	Moving forward: Bronchiectasis and chronic suppurative lung disease in children and adults in the 21st century. <i>Respirology</i> , 2019, 24, 1051-1052.	2.3	1
49	Trainee concerns regarding the Specialty Certificate Examination: results of a British Thoracic Society national survey: MRCP (UK) response. <i>Thorax</i> , 2014, 69, 771-772.	5.6	0
50	Reply to Zelyas and Robinson. <i>Clinical Infectious Diseases</i> , 2016, 63, 142.2-143.	5.8	0
51	Response. <i>Chest</i> , 2019, 155, 1082-1083.	0.8	0
52	Providing evidence-based care for adult patients with bronchiectasis. <i>Nursing Standard (Royal)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14	0.1	0